{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:36:26Z","timestamp":1785458186388,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cmi.2022.10.011","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T05:59:51Z","timestamp":1665640791000},"page":"366-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data"],"prefix":"10.1016","volume":"29","author":[{"given":"Dani","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Ashkenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Schneerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Farzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Bialik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Meron-Sudai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Asato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophy","family":"Goren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer Ziv","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khitam","family":"Muhsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calman A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.10.011_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to Shigella and enterotoxigenic Escherichia coli diarrhoea: the global burden of disease study 1990-2016","volume":"18","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.011_bib2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.011_bib3","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1017\/S0950268814000260","article-title":"Recent trends in the epidemiology of shigellosis in Israel","volume":"142","author":"Cohen","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.cmi.2022.10.011_bib4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/oxfordjournals.aje.a116134","article-title":"Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile","volume":"134","author":"Ferreccio","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.cmi.2022.10.011_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/infdis\/164.3.533","article-title":"Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei","volume":"164","author":"Formal","year":"1991","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.011_bib6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/vaccines10091376","article-title":"The Shigella vaccines pipeline","volume":"10","author":"MacLennan","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cmi.2022.10.011_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.10.011_bib8","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.10.011_bib9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.011_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101076","article-title":"Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: results from a phase 2b randomized, placebo-controlled challenge study in adults","volume":"39","author":"Frenck","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cmi.2022.10.011_bib11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cmi.2022.10.011_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103310","article-title":"Human challenge study with a Shigella bioconjugate vaccine: analyses of clinical efficacy and correlate of protection","volume":"66","author":"Talaat","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cmi.2022.10.011_bib13","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/21645515.2019.1606971","article-title":"Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis","volume":"15","author":"Cohen","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2022.10.011_bib14","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.vaccine.2019.10.046","article-title":"Updates on immunologic correlates of vaccine-induced protection","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.10.011_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1128\/jcm.27.1.162-167.1989","article-title":"Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections","volume":"27","author":"Cohen","year":"1989","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.10.011_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2022.10.011_bib17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/infdis\/jiq152","article-title":"Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials","volume":"203","author":"Gilbert","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.011_bib18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1541-0420.2008.01106.x","article-title":"Related causal frameworks for surrogate outcomes","volume":"65","author":"Joffe","year":"2009","journal-title":"Biometrics"},{"key":"10.1016\/j.cmi.2022.10.011_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12874-019-0687-y","article-title":"Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy","volume":"19","author":"Callegaro","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cmi.2022.10.011_bib20","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.10.011_bib21","first-page":"780","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.cmi.2022.10.011_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1214\/18-AOAS1237","article-title":"Nonparametric inference for immune response thresholds of risk in vaccine studies","volume":"13","author":"Donovan","year":"2019","journal-title":"Ann Appl Stat"},{"key":"10.1016\/j.cmi.2022.10.011_bib23","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.011_bib24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/jcm.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.cmi.2022.10.011_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/clinids\/15.2.346","article-title":"Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides","volume":"15","author":"Robbins","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.10.011_bib26","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/iai.61.9.3678-3687.1993","article-title":"Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids","volume":"61","author":"Taylor","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.cmi.2022.10.011_bib27","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/infdis\/jiab462","article-title":"Critical needs in advancing Shigella vaccines for global health","volume":"225","author":"MacLennan","year":"2022","journal-title":"J\u00a0Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X22005250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:29Z","timestamp":1761118409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X22005250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1198743X22005250"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.10.011","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}